PRF Technologies Secures New $15M Highly Dilutive Equity Line with Yorkville
PRFX sits 28% above its 52-week low of $1.28 on light trading volume (0.2× avg).
Summary
PRF Technologies has entered into a new $15.0 million dilutive equity line agreement with Yorkville, replacing a recently exhausted $10.0 million facility, to secure ongoing capital.
Key Events · Financing and Capital Events · PRFX
-
New $15.0 Million Equity Line
PRF Technologies entered into a Standby Equity Purchase Agreement with Yorkville for up to $15.0 million in ordinary shares over 36 months.
-
Highly Dilutive Terms
Shares will be sold at 97% of the lowest of three daily VWAPs, indicating significant potential dilution for existing shareholders.
-
Replaces Exhausted Prior Facility
This agreement follows the full utilization and termination of a previous $10.0 million equity line with Yorkville, highlighting the company's ongoing need for capital.
-
Commitment Fee Paid in Shares
A commitment fee of 1.0% of the total amount was agreed upon, with the first installment paid via the issuance of 20,276 ordinary shares.
Analysis · PRFX · Life Sciences
This new Standby Equity Purchase Agreement (SEPA) provides PRF Technologies with access to up to $15.0 million in capital over 36 months. While securing financing is crucial for the company's operations, the agreement is highly dilutive, especially given the company's micro-cap status. The previous $10.0 million SEPA with Yorkville was fully utilized, indicating a continuous and substantial need for capital. The terms, allowing sales at a discount to VWAP, suggest the company is raising funds under challenging conditions, which will significantly impact existing shareholders.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $1.28 to $17.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.